Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood

Abstract

Objectives:

Despite the global impact of the Respiratory Syncytial Virus (RSV) infection in children, only one monoclonal antibody (Palivizumab) has been approved for clinical use. However, advances in the knowledge of RSV immunology may enable the development of safe and effective new vaccines and monoclonal antibodies in a few years. The purpose of this review is to summarize available data on approved and developing passive and active immunizations against RSV in childhood and pregnancy.

Data source:

A non-systematic review of RSV immunoprophylaxis in childhood and pregnancy was carried out in PubMed, path.org and clinical trial registries, without language restrictions, up to September 2022.

Data synthesis:

Three monoclonal antibodies and 17 active immunization candidates are under development in phase 1 to 3 clinical studies. Regarding the first group, Nirsevimab is a monoclonal antibody with a prolonged half-life whose approval for clinical use is expected in the next months. Among the vaccines under development, six techniques are being used: protein subunit, viral particles, live attenuated virus, recombinant viral vector, chimeric, and mRNA. The first two approaches are being tested primarily in pregnancy, while the others are being developed for the pediatric population.

Conclusion:

The approval of extended half-life monoclonal antibodies is the next expected advance in RSV prevention, although the costs may be a barrier to the implementation. Regarding active immunizations, maternal and infant vaccination are complementary strategies and there are many promising candidates in clinical studies using different platforms.

KEYWORDS
Respiratory Syncytial virus; Vaccines; Monoclonal antibody; Pregnant women; Child

Introduction

The Respiratory Syncytial Virus (RSV) is the main agent causing hospitalizations for lower respiratory tract infections (LRTIs) in children, especially those related to bronchiolitis and pneumonia. Contrary to the epidemiological changes observed in vaccine-preventable diseases in recent decades, the impact of LRTIs secondary to RSV has remained relatively unchanged. In children under 5 years of age, annual estimates of the global impact of RSV-related LRTIs is 33 million, with 3.6 million hospitalizations and 26,300 in-hospital deaths. The highest incidence of hospitalization occurs in children under 6 months of age and it is estimated that approximately 99% of deaths occur in low- and middle-income countries.¹,³,⁴ Some groups are particularly vulnerable, such as preterm infants, those with congenital heart disease, bronchopulmonary dysplasia, genetic syndromes, and neuromuscular diseases.⁵ The impact of RSV-related LRTIs causing hospitalizations and deaths has also been increasingly recognized in the elderly.⁶ The most commonly used epidemiological surveillance criteria are based on the detection of the influenza virus, which restricts the actual identification of the impact and seasonality related to the RSV.⁷

Marked reductions in the incidence of LRTIs due to RSV have been reported in several countries during periods of more controlled social distancing, with activity restrictions aimed at attenuating the COVID-19 pandemic.⁸,⁹,¹⁰,¹¹ Despite robust epidemiological evidence of the effectiveness of non-pharmacological measures in controlling the spread of RSV, maintaining these efforts is not feasible and the incidence of RSV-related LRTIs has increased significantly soon after the resumption of usual activities in most countries.¹²,¹³

An effective immunoprophylaxis regimen is expected to be the primary public health measure with the potential to have a significant protective impact on RSV infections in infants. Despite the need for new interventions and major investments to develop safe and effective immunizations against RSV in recent decades, only passive immunization using the monoclonal antibody Palivizumab is currently approved. However, there is an expectation that at least one monoclonal antibody with a long half-life (Nirsevimab) will soon be approved for clinical use.¹⁴

The immune response to RSV is one of the most important barriers to the development of active immunizations. The natural immune response against RSV is partial and incomplete. Although there are more concerns with individuals in high-risk groups for severity, there are many available epidemiological data reinforcing that reinfections occur throughout life, including by the same strain.¹⁵,¹⁶

RSV structure

The RSV is a single-stranded negative-sense RNA virus that belongs to the Paramyxoviridae family, Pneumovirinae subfamily. Its two antigenic subtypes, A and B, circulate simultaneously annually and exhibit many genomic divergences. Among the eight RSV structural proteins, three are surface glycoproteins [small hydrophobic (SH), attachment (G) and fusion (F)], the last two of which are very important for the immune response against RSV and its pathogenesis¹⁷ F-glycoprotein is the most promising target in the development of vaccines and monoclonal antibodies due to its crucial role in viral entry into human cells, showing several antigenic sites with the potential to induce neutralizing antibodies (very conserved in A and B subtypes). F-glycoprotein has two conformations, one pre-fusion, and one post-fusion.¹⁵ After the RSV binds to the target cell, the F-glycoprotein irreversibly changes from the first to the second conformation, which involves important structural changes that lead to the loss of many important antigenic sites, such as Ø and V. For these reasons, the pre-fusion F glycoprotein (pre-F) is the most promising target for the induction of neutralizing antibodies. Knowledge of the greater potential of pre-F glycoprotein compared to post-fusion (post-F) F glycoprotein for inducing the immune response has revolutionized the prospect of obtaining the RSV vaccine. Although neutralizing antibodies against glycoproteins G and F (pre-F and post-F) have been associated with protection in clinical studies, a precise correlate of protection has not yet been defined.¹⁸

History of the RSV vaccine development

In the 1960s, an initially well-tolerated, formalin-inactivated RSV vaccine was associated with increased RSV severity in vaccinated infants without previous RSV infection, which led to a markedly increased risk of hospitalizations (it was related to two deaths).¹⁹ Many hypotheses were considered for such unfavorable results; the central idea is that there was complement activation and Th2 polarization of the immune response.²⁰ These findings have posed some difficulties regarding the RSV vaccine development related to safety issues, especially in populations without prior RSV immunity. In addition to these disappointing results, the abovementioned factors, such as epidemiological data based on influenza surveillance, the evolution of the immune response knowledge, plus the lack of an ideal animal model (since mice are not susceptible to RSV), can be listed as additional barriers to the development of a vaccine against this agent in recent decades.¹⁴,¹⁵

A major advance regarding active immunizations was the PREPARE study, a phase 3 clinical trial of a pre-F RSV protein nanoparticle vaccine aimed at pregnant women. A total of 4,636 pregnant women with a gestational age of 28 to 36 weeks were randomized in a 2:1 ratio to receive a single intramuscular dose of vaccine or placebo. The study did not meet the estimated primary endpoint for efficacy, which was at least a 50% reduction in physician-identified RSV-associated lower respiratory tract infections within the first 90 days of life. However, although the overall outcomes were not met (vaccine efficacy was 39.4%; 97.52% confidence interval [CI], -1.0 to 63.7%), the efficacy in South African infants was statistically significant (vaccine efficacy 57.0%; 95%CI 32.7%-72.5%). While the reasons for the differences in efficacy between participants from South Africa and those from other countries have been the subject of extensive debate, this was the first study to demonstrate the effectiveness of a maternal RSV vaccine in any subgroup of participants.²¹

Several active immunization strategies are currently in clinical studies, which include maternal immunization, viral vector, subunit vaccines, chimeric and live attenuated vaccines.¹⁴,¹⁵

The main objective of this review is to describe the current status and prospects of active and passive RSV immunizations.

Methods

A non-systematic review was performed to describe current and future strategies for pediatric RSV immunization, targeting vaccines and monoclonal antibodies approved for clinical use or those candidates in development through clinical phase studies. Data search was performed on PubMed, clinical trial registries, and PATH VSR Vaccine and mAb snapshot (last updated September 9, 2022), including immunizations in children under 18 years of age or during pregnancy, with no language restrictions (up to September 10, 2022).²² Studies on vaccines or interventions with immunoprophylaxis in the elderly are beyond the scope of this review and will not be detailed throughout this manuscript.

Overall strategies

The evolution in knowledge about the immune response against RSV, as well as the increasing identification of the RSV disease burden, have led to an important increase in the number of promising candidates for active and passive immunization. The ideal strategy to protect mainly infants and preschool children includes a combination of approaches, such as active and passive immunization. For infants less than six months of age, maternal immunization of pregnant women proposes protein-based vaccines using both vaccine subunits containing stabilized pre-F, or viruslike particles containing protein F. For older children, active immunization with live vaccines with the attenuated virus, chimeric vaccines, or vaccines based on recombinant vectors is the main strategies. The safety and efficacy of mRNA vaccines against SARS-CoV-2 also reinforced the potential of this platform as a viable strategy for RSV vaccination during childhood.²³ The ideal vaccine should prevent not only disease severity but also reduce transmission.

Although the development of active immunization for pregnant women and infants is one of the main goals to control RSV-related LRTI burden in infants, the use of monoclonal antibodies will continue to play a role as a complementary strategy. Transplacental antibodies are transferred mainly in the third trimester of pregnancy and preterm infants, one of the highest-risk groups, cannot be protected by maternal immunization. Moreover, the seasonality of RSV may not coincide with the period of greatest protection of maternal vaccination, making the use of monoclonal antibodies an interesting option to cover the period of greatest risk of the year in situations where other forms of immunization are not feasible. Currently, there are 17 vaccines and three monoclonal antibodies in ongoing or completed clinical trials, as shown in Table 1. Figure 1 summarizes the overview of the main vaccine groups in all preclinical and clinical studies for the different target populations.¹⁴,¹⁵,¹⁶,²²

Table 1
Summary of RSV immunizations in children and pregnant women undergoing evaluation in clinical trials.

Group	Immunizer	Manufacturer	Target population	Viral target	Administration route	Clinical phase	Clinical trial registration number (clinicaltrials.gov)	Results
Particle	V-306	Virometix	Pregnant women	V-306	IM	1 (ongoing)	NCT04519073	Not available
Protein subunit	DS-Cav1	NIH/NIAID	Pregnant women	Pre-F	IM	1 (completed)	NCT03049488	Safe and well tolerated, with the induction of neutralizing antibodies for more than 44 weeks
	RSVpreF3	GlaxoSmithKline	Pregnant women	Pre-F3	IM	2 (completed) and 3 (interrupted)	NCT04126213 NCT04605159	Potent induction of neutralizing antibodies and transplacental passage of antibodies in phase 2. Interrupted due to a safety sign in phase 3
	RSVpreF	Pfizer	Pregnant women	Pre-F	IM	2b (completed) 3 (ongoing)	NCT04785612 NCT04424316	Safe and well tolerated
Live attenuated vaccines	VAD00001	Sanofi Pasteur	Pediatric	All viral proteins	IN	1 and 2 (ongoing)	NCT04491877 NCT04491877	Not available
	RSV 6120/∆NS1	NIAID	Pediatric	All viral proteins	IN	1 (ongoing)	NCT03596801	Not available
	RSV 6120/F1/G2/∆NSI	NIAID	Pediatric	All viral proteins	IN	1 (ongoing)	NCT03596801	Not available
	RSV 6120/∆NS2/1030s	NIAID	Pediatric	All viral proteins	IN	1 (ongoing)	NCT03387137 NCT03916185	Not available
	RSV LID/∆M2-2/1030s	NIAID and Sanofi Pasteur	Pediatric	All viral proteins	IN	1 (ongoing)	NCT04520659	Not available
	RSV ∆NS2/∆1313 / I1314L	NIAID	Pediatric	All viral proteins	IN	1 (completed) 2 (ongoing)	NCT03916185 NCT01893554 NCT03916185	Safe and immunogenic
	IT-RSV∆G	Intravacc	Pediatric	All viral proteins	IN	1 (completed)	NTR7173	Safe and well tolerated
	MV-012-968	Meissa	Pediatric	All viral proteins	IN	1 and 2 (ongoing)	NCT04909021 NCT04690335	Not available
	RSV-MinL4.0	Codagenix	Pediatric	All viral proteins Pre-F	IN	1 (ongoing)	NCT04919109	Not available
Recombinant viral vector	Ad26.RSV.pre-F	Johnson & Johnson	Pediatric		IM	2 (completed)	NCT03606512	Safe and immunogenic
Chimeric	rBCG-N-hRSV	Pontifícia Universidad Católica de Chile	Pediatric	N	ID	1 (completed)	NCT03213405	Safe
	SeV-RSV	NIAID	Pediatric	F	IN	1 (completed)	NCT03473002	Safe
mRNA	mRNA-1345	Moderna	Pediatric	Pre-F	IM	1 (ongoing)	NCT04528719	Not available
Monoclonal antibodies	Nirsevimab	AstraZeneca and Sanofi Pasteur	Pediatric (preterm and full-term)	Site Ø (pre-F)	IM	3 (completed)	NCT03959488 NCT03979313	Reduction of 74.1% (95% CI, 49.6 to 87.1%) in medical care related to the RSV
	Clesrovimab	Merck	Pediatric (preterm and full-term)	Site IV (pre and post-F)	IM or IV	2a (completed) 2b/3 (ongoing)	NCT03524118 NCT04938830 NCT04767373	Reduction of symptomatic disease
	RSM-01	Bill and Melinda Gates Medical Research Institute	Pediatric	Site Ø (pre-F)	IM or IV	1 (ongoing)	NCT05118386	Not available

• Legend: IV: intravenous, ID: intradermal, IM: intramuscular, IN: intranasal.

Figure 1
Main RSV vaccines and monoclonal antibodies in development.²² *Adapted from https://www.path.org/resources/rsv-vac cine-and-mab-snapshot/. Reproduced by permission of Path.

Active maternal immunization

Extensive epidemiological evidence highlights the potential of maternal vaccination to protect infants from diseases such as pertussis, influenza, and COVID-19.²⁴ For the prevention of RSV, the objective is to promote reinforcement of previous immunity to RSV through the vaccination of pregnant women.

Particle-based vaccines

This group of vaccines is at an early stage of development but has the potential to induce a potent immune response, as it can display multiple antigens using F protein-based nanoparticles. As mentioned above, the PREPARE study was the first to report the efficacy of a maternal RSV vaccine in the subset of South African infants, despite the primary efficacy endpoint in the overall groups of participants not being met.²¹ In addition, a phase 1 study is being conducted in healthy adult women with V-306, a candidate based on the RSV F protein site II antigen, with no results yet available.¹⁴

Protein subunit

Due to the previous experience of inactivated vaccine induction of exacerbated respiratory disease in children with no previous RSV immunity, potential vaccines using this platform were designed for pregnant women and the elderly. Several attempts to develop a subunit vaccine using post-F antigen have previously failed. Currently, most candidates are based on a stabilized pre-F antigen. The phase 1 study evaluating the DS-Cav1 candidate to the pre-F subunit was published in 2021. Ninety-five healthy adults were enrolled for safety and immunogenicity assessment of three different doses (50, 150 and 500 μg) and comparison of a single dose versus two doses (12-week interval), with or without aluminum hydroxide adjuvant. DS-Cav1 was shown to be safe and well tolerated. Additionally, the vaccine induced a robust and sustained boost in neutralizing antibodies above the baseline for at least 44 weeks, regardless of the dose, number of injections, and use of adjuvants. These results reinforce the potential of this vaccine to provide protection against RSV throughout an entire viral season.²⁵

RSVpreF3, a maternal vaccine using pre-F protein, is already in phase 3 studies (Grace trial). However, although it has been shown in previous phases to attain high titers of neutralizing antibodies, the inclusion of subjects in this study was stopped in February 2022, due to a safety sign.¹⁴

A third candidate is an RSV-stabilized pre-fusion F subunit vaccine (RSVpreF). In the phase 2b study, RSVpreF was compared by administering it alone and by co-administering it with Tdap, with or without adjuvant, in healthy non-pregnant adult women. The vaccine showed to be safe and well tolerated. Immune responses against tetanus and diphtheria were non-inferior when co-administered with Tdap, although the non-inferiority criteria were not met for pertussis. The phase 3 study of RSVpreF in pregnant women started in 2021 and recruitment is still ongoing.²⁶

Active pediatric immunization

Live attenuated vaccine

This has been one of the most promising vaccine groups for infants and older children as they were developed to induce a robust immune response through attenuated local infection by stimulating the humoral and cell immune systems. In addition, live attenuated vaccines were not associated with increased RSV disease severity, although they were related to upper airway disease; they are administered intranasally, which also seems to be an advantage from the point of view of acceptance by the family and the children. There are nine candidates currently in phase 1 and 2 clinical trials. In one analysis of seven phases, 1 trial in 239 infants aged 6 to 24 months, evaluating five vaccines in development that induced neutralizing antibody responses in ≥ 80% among those vaccinated, the effectiveness in reducing RSV episodes of acute respiratory illness requiring medical treatment was 67% (95% CI, 24 to 85%), with a reduction in medical care for RSV-related LRTIs of 88% (95% CI, -9 to 99; P = 0.04). A fourfold increase in neutralizing antibody levels was strongly associated with protection against both of the aforementioned clinical outcomes.²⁷

Recombinant viral vector vaccine

This group of vaccines has been widely used against SARS-CoV-2 and consists of viruses with replication-deficient RSV genes. Its rationale is to induce humoral and cell immunity. For children, the main candidate is pre-F.Ad26.RSV, which uses an adenoviral vector for pre-fusion F protein expression. The phase 2 results of the study in previously RSV seropositive infants in the second year of life showed that pre-F. Ad26.RSV was safe and immunogenic. A second similar phase 2 study in previously seronegative children for RSV, also aged between 12 and 24 months, is also being carried out, but the results are not yet available.¹⁴

Chimeric vaccine

The main characteristic of this group of vaccines is the expression of the RSV protein in viruses or bacteria with more favorable safety profiles and antigen presentation, compared to vector-based vaccines. One such potential candidate is based on recombinant BCG N protein via intradermal administration (rBCG-N-hRSV); this vaccine was shown to be safe and immunogenic in a phase 1 study in healthy adults.²⁸ The second candidate is SeVRSV, a vaccine based on the Sendai virus (SeV), which is efficient for replicating the gene that carries the RSV fusion protein (F). This vaccine was shown to be safe in phase 1 studies in which the vaccine was administered intranasally to healthy adults.²⁹

mRNA vaccines

The success of the mRNA vaccine against SARS-CoV-2 makes the use of this platform a very interesting option for the development of vaccines against RSV.²³ Interestingly, previous studies identifying pre-F RSV as the preferred vaccine antigen have supported the development of the mRNA-based SARS-CoV-2 vaccine.³⁰ Currently, a phase 1 study of the mRNA-1345 vaccine, which encodes stabilized pre-F RSV, is underway in healthy women of childbearing age, the elderly, and RSV-seropositive children (aged 12 to 59 months); these results are expected by 2023. As an additional benefit, the use of mRNA vaccines against RSV has the potential to be combined with mRNA vaccines against SARS-CoV-2 and influenza, currently being tested in adults.¹⁴

Passive immunization

Palivizumab (Synagis®, AstraZeneca AB, Sweden) is currently the only monoclonal antibody clinically approved and used in recent decades. The efficacy and safety of palivizumab were demonstrated in three randomized, placebo-controlled clinical trials. A meta-analysis of 2,831 high-risk neonates (preterm gestation ≤ 35 weeks, bronchopulmonary dysplasia, and congenital heart disease) showed that the use of palivizumab was not related to an increased risk of adverse events and was associated with a reduction in RSV-related hospitalizations from 101 to 50/1,000 (relative risk [RR] 0.49, 95% CI 0.37-0.64) and reductions in pediatric intensive care unit admissions from 34 to 17/1000 (RR 0.5, 95%CI 0.3 to 0.81).³¹ Palivizumab has been used in many countries and, although indications may vary, most include bronchopulmonary dysplasia, congenital heart disease, and preterm infants born with a gestational age ≤ 28 weeks and 6 days. In post-licensing surveillance studies, the efficacy of palivizumab was similar, although the impact varied in different settings.³² The inclusion of preterm infants born between 29 and 34 weeks of gestational age has been a matter of debate. In 2014, the American Academy of Pediatrics amended the policy, restricting its use in the latter group.³³ Although it is not a uniform finding, some studies suggest an increase in RSV-related hospitalization in infants born within the gestational age range in which palivizumab use was restricted.³⁴,³⁵,³⁶ This debate on a more restrictive use reinforces that, despite the effectiveness and efficacy demonstrated by palivizumab, the need for monthly administration and costs are still important barriers to its universal use, especially in developing countries and in infants without risk factors.¹⁶

Two other monoclonal antibody candidates did not pass previous stages of clinical studies. Motavizumab has not been shown to be superior to palivizumab and has been associated with a higher incidence of skin rash in phase 3 studies.³⁷ The development of suptavumab was also discontinued because it did not meet the endpoints of efficacy clinical trials in phase 3 studies, mainly due to a lack of activity against RSV subtype B strains.³⁸

Nirsevimab has phase 3 studies that indicate it is the most promising of these new, long half-life monoclonal antibodies. It focuses on the Ø site of the F protein, with a single dose proposal for protection throughout the season, being a promising candidate for RSV immunoprophylaxis. In 2020, a phase 2b, randomized, placebo-controlled clinical trial evaluated nirsevimab in a single 50mg intramuscular dose in 1,453 healthy preterm infants born at a gestational age between 29 and 34 weeks and 6 days and reported a reduction in the risk of RSV hospitalization of 78.4% (95% CI, 51.9 to 90.3), maintained for 150 days after dose administration.³⁹ In 2022, a phase 3, randomized, placebo-controlled clinical trial evaluating the efficacy of nirsevimab in 1,490 late preterm (at least 35 weeks of gestational age) or full-term neonates reported a 74.1% reduction (CI 95%, 49.6 to 87.1) in medical care related to lower respiratory tract infections caused by RSV, the main outcome of the study.⁴⁰ Regarding safety, none of the abovementioned studies identified an increase in adverse events in subjects receiving nirsevimab when compared to placebo. Based on these promising results, nirsevimab is expected to gain regulatory approval for clinical use in 2023, possibly being the first effective intervention for RSV since the advent of palivizumab.¹⁴,³⁸,⁴⁰

Clesrovimab (MK-1654) is another monoclonal antibody candidate, with similarities to nirsevimab and targeting site IV of the F protein. Recruitment for this phase 2a study has been completed and phase 2b/3 has started and is expected to be completed in 2024.

All these new options under development can help to reduce costs and increase accessibility, as this is one of the main points related to the use of monoclonal antibodies. RSM-01, which is presently in phase 1, is expected to cost significantly less than the current monoclonal antibodies. Finally, the development of a biosimilar palivizumab, as well as its nasal administration, both in clinical trials with no results yet, can help to reduce costs and increase accessibility, especially in lower-income countries, exactly in places where RSV-related morbidity and mortality rates are higher.¹⁴

Conclusions

Despite the great impact of vaccines on the epidemiology of infectious diseases for children in recent decades, the impact of RSV-related LRTIs has remained unchanged. Several challenges, particularly those related to the immune response to this agent, have greatly hindered progress toward attaining consistent immunoprevention of RSV infection. In recent years, several advances have been made regarding the understanding of the immunogenicity of potential vaccines against RSV due to the immunogenic potential of the pre-F conformation of the F glycoprotein, making the development of an effective and long-lasting active immunization more feasible in the coming years. It is expected that several of these strategies, currently under development, will be complementary, with vaccination in infants combined with immunization of pregnant women, aiming to protect infants in their first months of life. For preterm infants, the use of monoclonal antibodies is the main preventive strategy, as transplacental antibodies are transferred to the fetus during the third trimester of pregnancy. Currently, only passive immunization with palivizumab is available in clinical practice, with the duration of protection and high costs being important barriers to achieving a high impact on RSV epidemiology.

The prospect of effective active RSV immunization in the coming years is promising, although the immediate reality for most countries is still the use of monoclonal antibodies in high-risk groups. In an optimistic scenario of new, more effective, long-lasting and accessible interventions being available only in a period that should vary between 3 and 5 years, knowledge of the local epidemiology and seasonality is very important to guide the rational use of resources.

References

• ¹
  Shi T, McAllister DA, O’Brien KL, Simoes EA, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390:946-58.
• ²
  Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-55.
• ³
  Stein RT, Bont LJ, Zar H, Polack FP, Park C, Claxton A, et al. Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis. Pediatr Pulmonol. 2017;52:556-69.
• ⁴
  Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399:2047-64.
• ⁵
  Scheltema NM, Gentile A, Lucion F, Nokes DJ, Munywoki PK, Madhi SA, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017;5. e984-e991. Erratum in: Lancet Glob Health. 2017;5:e1190.
• ⁶
  Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: A Systematic Review and Meta-Analysis. J Infect Dis. 2020;222: S577-83.
• ⁷
  Kim L, Rha B, Abramson JS, Anderson LJ, Byington CL, Chen GL, et al. Identifying gaps in respiratory syncytial virus disease epidemiology in the United States prior to the introduction of vaccines. Clin Infect Dis. 2017;65:1020-5.
• ⁸
  Friedrich F, Ongaratto R, Scotta MC, Veras TN, Stein RT, Lumertz MS, et al. Early impact of social distancing in response to Coronavirus disease 2019 on hospitalizations for acute bronchiolitis in infants in Brazil. Clin Infect Dis. 2021 ;72:2071 -5.
• ⁹
  Varela FH, Sartor ITS, Polese-Bonatto M, Azevedo TR, Kern LB, Fazolo T, et al. Rhinovirus as the main co-circulating virus during the COVID-19 pandemic in children. J Pediatr (Rio J). 2022. S0021-7557(22)00044-4.
• ¹⁰
  Yeoh DK, Foley DA, Minney-Smith CA, Martin AC, Mace AO, Sikazwe CT, et al. Impact of Coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian Winter. Clin Infect Dis. 2021;72:2199-202.
• ¹¹
  Nolen LD, Seeman S, Brüden D, Klejka J, Desnoyers C, Tiesinga J, et al. Impact of social distancing and travel restrictions on non-coronavirus disease 2019 (Non-COVID-19) respiratory hospital admissions in young children in rural Alaska. Clin Infect Dis. 2021;72:2196-8.
• ¹²
  Eden JS, Sikazwe C, Xie R, Deng YM, Sullivan SG, Michie A, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun. 2022;13:2884.
• ¹³
  Bardsley M, Morbey RA, Hughes HE, Beck CR, Watson CH, Zhao H, et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis. 2022: S1473-3099(22)00525-4.
• ¹⁴
  Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2022:S1473-3099(22)00291-2. doi: 10.1016/S1473-3099(22) 00291 -2. Epub ahead of print.
  » https://doi.org/10.1016/S1473-3099(22) 00291 -2
• ¹⁵
  Mejias A, Rodriguez-Fernández R, Oliva S, Peeples ME, Ramilo O. The journey to a respiratory syncytial virus vaccine. Ann Allergy Asthma Immunol. 2020;125:36-46.
• ¹⁶
  Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in low- and middle-income countries: challenges and opportunities. Vaccines. 2021;9:961.
• ¹⁷
  McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011;85:7788-96.
• ¹⁸
  Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transi Med. 2015;7. 309ra162.
• ¹⁹
  Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89:449-63.
• ²⁰
  Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002;196:859-65.
• ²¹
  Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020;383: 426-39.
• ²²
  PATH, [cited 2022 Sep 10]. Available from: https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/.
  » https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/.
• ²³
  Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-15.
• ²⁴
  Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K, et al. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol. 2022;226:459-74.
• ²⁵
  Ruckwardt TJ, Morabito KM, Phung E, Crank MC, Costner PJ, Holman LA, et al. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DSCav1: a phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir Med. 2021:1111-20. 9.
• ²⁶
  Peterson JT, Zareba AM, Fitz-Patrick D, Essink BJ, Scott DA, Swanson KA, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a Tetanus, Diphtheria, and Acellular Pertussis vaccine. J Infect Dis. 2022;225:2077-86.
• ²⁷
  Karron RA, Atwell JE, McFarland EJ, Cunningham CK, Muresan P, Perlowski C, et al. Live-attenuated vaccines prevent respiratory syncytial virus-associated illness in young children. Am J Respir Crit Care Med. 2021;203:594-603.
• ²⁸
  Abarca K, Rey-Jurado E, Muñoz-Durango N, Vázquez Y, Soto JA, Gálvez NM, et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine. 2020;27:100517.
• ²⁹
  Scaggs Huang F, Bernstein DI, Slobod KS, Portner A, Takimoto T, Russell CJ, et al. Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Hum Vaccin Immunother. 2021;17:554-9.
• ³⁰
  Corbett KS, Edwards DK, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586: 567-71.
• ³¹
  Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Acute Respiratory Infections Group, ed. Cochrane Database Syst Rev. 2013(4):CD006602.
• ³²
  Moore HC, de Klerk N, Richmond PC, Fathima P, Xu R, Keil AD, et al. Effectiveness of palivizumab against respiratory syncytial virus: cohort and case series analysis. J Pediatr. 2019;214: 121-7. e1.
• ³³
  American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134:415-20.
• ³⁴
  Zembles TN, Bushee GM, Willoughby RE. Impact of American Academy of Pediatrics Palivizumab Guidance for children ≥29 and <35 weeks of gestational age. J Pediatr. 2019;209:125-9.
• ³⁵
  Fergie J, Goldstein M, Krilov LR, Wade SW, Kong AM, Brannman L. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017. Hum Vaccin Immunother. 2021;17:1536-45.
• ³⁶
  Rajah B, Sánchez PJ, Garcia-Maurino C, Leber A, Ramilo O, Mejias A. Impact of the updated guidance for palivizumab prophylaxis against respiratory syncytial virus infection: a single center experience. J Pediatr. 2017;181:183-8. e1.
• ³⁷
  Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics. 2010;125:e35-51.
• ³⁸
  Simões EA, Forleo-Neto E, Geba GP, Kamal M, Yang F, Cicirello H, et al. S Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis. 2021;73:e4400-8.
• ³⁹
  Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383:415-25.
• ⁴⁰
  Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386:837-46.

Publication Dates

• Publication in this collection
  28 Apr 2023
• Date of issue
  Mar-Apr 2023

History

• Received
  02 Oct 2022
• Accepted
  04 Oct 2022
• Published
  17 Nov 2022